2,5-dihydro-2,5-dioxo-1h-azepines and 2,5-dihydro-2-oxo-1h-azepines and the use thereof as excitatory amino acid and glycine receptor antagonists
CA 2098446 A1 · Owner: Keana, John F. W. · Inventors: Koroshetz, Walter J.; Huettner, James E.; Rees, Alun H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods of treating or preventing neuronal loss associated with stroke ischemia, CNS trauma, hypoglycemia and surgery as well as treating, neurodegenerative diseases including Alzheimer's disease amyotrophic lateral, sclerosis, Huntington's disease and Down's syndrome treating or preventing, the adverse consequences of the hyperactivity of the excitatory amino acids as well as treating anxiety, chronic pain convulsions and inducing anesthesia, are disclosed by administering to an animal in need of such treatment a substituted benzazepine which has high binding to the glycine receptor.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 15, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 15, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 15, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.